# Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia

> **NCT01349790** · PHASE3 · COMPLETED · sponsor: **Octapharma** · enrollment: 40 (actual)

## Conditions studied

- Primary Thrombocytopenia

## Interventions

- **DRUG:** NewGam

## Key facts

- **NCT ID:** NCT01349790
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01349790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01349790, "Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01349790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*